147 related articles for article (PubMed ID: 34589973)
1. Efficacy of Taletrectinib (AB-106/DS-6051b) in
Ou SI; Fujiwara Y; Shaw AT; Yamamoto N; Nakagawa K; Fan F; Hao Y; Gao Y; Jänne PA; Seto T
JTO Clin Res Rep; 2021 Jan; 2(1):100108. PubMed ID: 34589973
[TBL] [Abstract][Full Text] [Related]
2. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Borazanci E; Shaw AT; Katayama R; Shimizu Y; Zhu VW; Sun TY; Wakelee HA; Madison R; Schrock AB; Senaldi G; Nakao N; Hanzawa H; Tachibana M; Isoyama T; Nakamaru K; Deng C; Li M; Fan F; Zhao Q; Gao Y; Seto T; Jänne PA; Ou SI
Clin Cancer Res; 2020 Sep; 26(18):4785-4794. PubMed ID: 32591465
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring
Fujiwara Y; Takeda M; Yamamoto N; Nakagawa K; Nosaki K; Toyozawa R; Abe C; Shiga R; Nakamaru K; Seto T
Oncotarget; 2018 May; 9(34):23729-23737. PubMed ID: 29805770
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Taletrectinib in Chinese Patients With
Li W; Xiong A; Yang N; Fan H; Yu Q; Zhao Y; Wang Y; Meng X; Wu J; Wang Z; Liu Y; Wang X; Qin X; Lu K; Zhuang W; Ren Y; Zhang X; Yan B; Lovly CM; Zhou C
J Clin Oncol; 2024 Jun; ():JCO2400731. PubMed ID: 38822758
[TBL] [Abstract][Full Text] [Related]
5. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
6. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Entrectinib in
Drilon A; Chiu CH; Fan Y; Cho BC; Lu S; Ahn MJ; Krebs MG; Liu SV; John T; Otterson GA; Tan DSW; Patil T; Dziadziuszko R; Massarelli E; Seto T; Doebele RC; Pitcher B; Kurtsikidze N; Heinzmann S; Siena S
JTO Clin Res Rep; 2022 Jun; 3(6):100332. PubMed ID: 35663414
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of crizotinib in patients with
Masuda K; Fujiwara Y; Shinno Y; Mizuno T; Sato J; Morita R; Matsumoto Y; Murakami S; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Ohe Y
J Thorac Dis; 2019 Jul; 11(7):2965-2972. PubMed ID: 31463126
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Wu YL; Yang JC; Kim DW; Lu S; Zhou J; Seto T; Yang JJ; Yamamoto N; Ahn MJ; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner KD; Goto K
J Clin Oncol; 2018 May; 36(14):1405-1411. PubMed ID: 29596029
[TBL] [Abstract][Full Text] [Related]
10. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.
Thawani R; Repetto M; Keddy C; Nicholson K; Jones K; Nusser K; Beach CZ; Harada G; Drilon A; Davare MA
bioRxiv; 2024 Jan; ():. PubMed ID: 38293020
[TBL] [Abstract][Full Text] [Related]
11. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Zhu VW; Lin YT; Kim DW; Loong HH; Nagasaka M; To H; Ang YL; Ock CY; Tchekmedyian N; Ou SI; Syn NL; Reungwetwattana T; Lin CC; Soo RA
J Thorac Oncol; 2020 Sep; 15(9):1484-1496. PubMed ID: 32360579
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
14. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Sehgal K; Piper-Vallillo AJ; Viray H; Khan AM; Rangachari D; Costa DB
Precis Cancer Med; 2020 Jun; 3():. PubMed ID: 32776005
[No Abstract] [Full Text] [Related]
15. Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Blumenthal GM; Luo L; He K; Fran I; Lemery S; Pazdur R
Oncologist; 2016 Aug; 21(8):974-80. PubMed ID: 27328934
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
Schneider JL; Muzikansky A; Lin JJ; Krueger EA; Lennes IT; Jacobson JO; Cheng M; Heist RS; Piotrowska Z; Gainor JF; Shaw AT; Dagogo-Jack I
JTO Clin Res Rep; 2022 Jul; 3(7):100347. PubMed ID: 35815322
[TBL] [Abstract][Full Text] [Related]
17. ADK-VR2, a cell line derived from a treatment-naïve patient with
Ruzzi F; Angelicola S; Landuzzi L; Nironi E; Semprini MS; Scalambra L; Altimari A; Gruppioni E; Fiorentino M; Giunchi F; Ferracin M; Astolfi A; Indio V; Ardizzoni A; Gelsomino F; Nanni P; Lollini PL; Palladini A
Transl Lung Cancer Res; 2022 Nov; 11(11):2216-2229. PubMed ID: 36519016
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Zeng L; Li Y; Xiao L; Xiong Y; Liu L; Jiang W; Heng J; Qu J; Yang N; Zhang Y
Onco Targets Ther; 2018; 11():6937-6945. PubMed ID: 30410351
[TBL] [Abstract][Full Text] [Related]
19. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Lim SM; Kim HR; Lee JS; Lee KH; Lee YG; Min YJ; Cho EK; Lee SS; Kim BS; Choi MY; Shim HS; Chung JH; La Choi Y; Lee MJ; Kim M; Kim JH; Ali SM; Ahn MJ; Cho BC
J Clin Oncol; 2017 Aug; 35(23):2613-2618. PubMed ID: 28520527
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
Vuong HG; Nguyen TQ; Nguyen HC; Nguyen PT; Ho ATN; Hassell L
Target Oncol; 2020 Oct; 15(5):589-598. PubMed ID: 32865687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
